Comparison of two common treatment methods in patients with Central Serous Chorioretinopathy (CSCR) referred to Imam Khomeini Hospital in Kermanshah in 2019 2020

Central serous cryortinopathy (CSCR) is an idiopathic disease most commonly seen in young men with a prevalence of 5.8 per 100,000. It is characterized by one or more cases of detachment serosa in the retinal neurosensory layer and may be associated with retinal pigment epithelial (RPE) detachment. Eighty patients were divided into two groups of exposure (receiving eplerenone at a dose of 25 mg for one week and then at a dose of 50 mg for three weeks) and without exposure (without medication). Effectiveness-related variables including best visual acuity as primary outcome, central macular thickness, and choroid thickness as secondary outcomes before, 1 month, and 3 months later were assessed and recorded. Information such as central macular thickness, choroid thickness of 500 and 1000 microns on the nasal side and temporal superior and inferior were measured. Data were analyzed by SPSS version 23 software. The mean reduction in choroid thickness in the macular group treated with eplerenone in the macula, as well as the 500 micron areas of the nasal, temporal, superior, and inferior, are: 12.90 ± 105.82 microns, 15.48 ± 95.17 microns, and 16.07 ±, respectively. 94.45 microns and 14.48 ± 94.96 microns and 15.10 ± 95.94 microns Also in the 1000 micron areas of the nasal, temporal, superior and inferior, respectively: .95 microns and 14.45 ± 95.81 microns and 13.39 ± 96.1.5 microns. It was concluded that treatment with eplerenone was significantly associated with a decrease in choroid thickness in the macula and areas of 500 and 1000 microns of the nasal, temporal, superior and inferior. In our study, 70% of patients were men with a mean age of about 39 It was a year. In our study, more than 30% of patients had low visual acuity at 0.5 on the LogMar scale at the end of the first month without receiving eplerenone.